Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?

Murugesan Manoharan, Martha A. Reyes, Bruce Kava, Rakesh Singal, Sandy S. Kim, Mark S. Soloway

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: To assess the safety of adjuvant chemotherapy in patients with neobladder reconstruction in comparison to ileal conduit, as radical cystectomy and urinary diversion is an effective curative surgical treatment for muscle-invasive and high-risk superficial bladder cancer, and adjuvant chemotherapy is usually considered for patients with clinical stage > T2 and nodal metastasis. PATIENTS AND METHODS: We analysed retrospectively patients who had had a radical cystectomy and urinary diversion between 1992 and 2004. Patients with high-risk disease who had adjuvant chemotherapy were identified and stratified based on the type of urinary diversion (ileal conduit or neobladder). The chemotherapy regimen, complications from the adjuvant chemotherapy and other relevant data were analysed. RESULTS: Overall, 343 patients had radical cystectomy, 40 had adjuvant chemotherapy; 25 had an ileal conduit and 15 had a neobladder. Patient characteristics including age, stage and follow-up were similar. In all, 55% of patients had grade 1 toxicity, 23% grade 2, 18% grade 3, and 13% grade 4. No patients had serious organ toxicity and none died. There were no significant differences in the toxicity among the two groups. CONCLUSIONS: Adjuvant chemotherapy appears to be safe in patients with a neobladder and equally safe in patients with an ileal conduit. Hence neobladder reconstruction should not be denied to patients with bladder cancer who are at high risk of recurrence and who might require adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1286-1289
Number of pages4
JournalBJU International
Volume96
Issue number9
DOIs
StatePublished - Dec 1 2005

Fingerprint

Urinary Diversion
Adjuvant Chemotherapy
Urinary Bladder Neoplasms
Cystectomy
Neoplasm Metastasis

Keywords

  • Adjuvant chemotherapy
  • Bladder cancer
  • Ileal conduit
  • Neobladder

ASJC Scopus subject areas

  • Urology

Cite this

Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder? / Manoharan, Murugesan; Reyes, Martha A.; Kava, Bruce; Singal, Rakesh; Kim, Sandy S.; Soloway, Mark S.

In: BJU International, Vol. 96, No. 9, 01.12.2005, p. 1286-1289.

Research output: Contribution to journalArticle

Manoharan, Murugesan ; Reyes, Martha A. ; Kava, Bruce ; Singal, Rakesh ; Kim, Sandy S. ; Soloway, Mark S. / Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?. In: BJU International. 2005 ; Vol. 96, No. 9. pp. 1286-1289.
@article{b98a5dc9e758408c89f19993c26101a8,
title = "Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?",
abstract = "OBJECTIVE: To assess the safety of adjuvant chemotherapy in patients with neobladder reconstruction in comparison to ileal conduit, as radical cystectomy and urinary diversion is an effective curative surgical treatment for muscle-invasive and high-risk superficial bladder cancer, and adjuvant chemotherapy is usually considered for patients with clinical stage > T2 and nodal metastasis. PATIENTS AND METHODS: We analysed retrospectively patients who had had a radical cystectomy and urinary diversion between 1992 and 2004. Patients with high-risk disease who had adjuvant chemotherapy were identified and stratified based on the type of urinary diversion (ileal conduit or neobladder). The chemotherapy regimen, complications from the adjuvant chemotherapy and other relevant data were analysed. RESULTS: Overall, 343 patients had radical cystectomy, 40 had adjuvant chemotherapy; 25 had an ileal conduit and 15 had a neobladder. Patient characteristics including age, stage and follow-up were similar. In all, 55{\%} of patients had grade 1 toxicity, 23{\%} grade 2, 18{\%} grade 3, and 13{\%} grade 4. No patients had serious organ toxicity and none died. There were no significant differences in the toxicity among the two groups. CONCLUSIONS: Adjuvant chemotherapy appears to be safe in patients with a neobladder and equally safe in patients with an ileal conduit. Hence neobladder reconstruction should not be denied to patients with bladder cancer who are at high risk of recurrence and who might require adjuvant chemotherapy.",
keywords = "Adjuvant chemotherapy, Bladder cancer, Ileal conduit, Neobladder",
author = "Murugesan Manoharan and Reyes, {Martha A.} and Bruce Kava and Rakesh Singal and Kim, {Sandy S.} and Soloway, {Mark S.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1111/j.1464-410X.2005.05822.x",
language = "English",
volume = "96",
pages = "1286--1289",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?

AU - Manoharan, Murugesan

AU - Reyes, Martha A.

AU - Kava, Bruce

AU - Singal, Rakesh

AU - Kim, Sandy S.

AU - Soloway, Mark S.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - OBJECTIVE: To assess the safety of adjuvant chemotherapy in patients with neobladder reconstruction in comparison to ileal conduit, as radical cystectomy and urinary diversion is an effective curative surgical treatment for muscle-invasive and high-risk superficial bladder cancer, and adjuvant chemotherapy is usually considered for patients with clinical stage > T2 and nodal metastasis. PATIENTS AND METHODS: We analysed retrospectively patients who had had a radical cystectomy and urinary diversion between 1992 and 2004. Patients with high-risk disease who had adjuvant chemotherapy were identified and stratified based on the type of urinary diversion (ileal conduit or neobladder). The chemotherapy regimen, complications from the adjuvant chemotherapy and other relevant data were analysed. RESULTS: Overall, 343 patients had radical cystectomy, 40 had adjuvant chemotherapy; 25 had an ileal conduit and 15 had a neobladder. Patient characteristics including age, stage and follow-up were similar. In all, 55% of patients had grade 1 toxicity, 23% grade 2, 18% grade 3, and 13% grade 4. No patients had serious organ toxicity and none died. There were no significant differences in the toxicity among the two groups. CONCLUSIONS: Adjuvant chemotherapy appears to be safe in patients with a neobladder and equally safe in patients with an ileal conduit. Hence neobladder reconstruction should not be denied to patients with bladder cancer who are at high risk of recurrence and who might require adjuvant chemotherapy.

AB - OBJECTIVE: To assess the safety of adjuvant chemotherapy in patients with neobladder reconstruction in comparison to ileal conduit, as radical cystectomy and urinary diversion is an effective curative surgical treatment for muscle-invasive and high-risk superficial bladder cancer, and adjuvant chemotherapy is usually considered for patients with clinical stage > T2 and nodal metastasis. PATIENTS AND METHODS: We analysed retrospectively patients who had had a radical cystectomy and urinary diversion between 1992 and 2004. Patients with high-risk disease who had adjuvant chemotherapy were identified and stratified based on the type of urinary diversion (ileal conduit or neobladder). The chemotherapy regimen, complications from the adjuvant chemotherapy and other relevant data were analysed. RESULTS: Overall, 343 patients had radical cystectomy, 40 had adjuvant chemotherapy; 25 had an ileal conduit and 15 had a neobladder. Patient characteristics including age, stage and follow-up were similar. In all, 55% of patients had grade 1 toxicity, 23% grade 2, 18% grade 3, and 13% grade 4. No patients had serious organ toxicity and none died. There were no significant differences in the toxicity among the two groups. CONCLUSIONS: Adjuvant chemotherapy appears to be safe in patients with a neobladder and equally safe in patients with an ileal conduit. Hence neobladder reconstruction should not be denied to patients with bladder cancer who are at high risk of recurrence and who might require adjuvant chemotherapy.

KW - Adjuvant chemotherapy

KW - Bladder cancer

KW - Ileal conduit

KW - Neobladder

UR - http://www.scopus.com/inward/record.url?scp=28544448334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544448334&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2005.05822.x

DO - 10.1111/j.1464-410X.2005.05822.x

M3 - Article

VL - 96

SP - 1286

EP - 1289

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -